Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.57 |
| ▸ | HTR2C | P28335 | 6/20 | 0.44 |
| ▸ | HTR2B | P41595 | 3/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | CCNK | O75909 | 1/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22341244 | 0.85 | PRCP (0.59) | PRCPHTR2CHTR2BTLR2TERT | |
| SCHEMBL15329272 | 0.84 | PRCP (0.70) | PRCPHTR2CHTR2BTLR2TERT | |
| SCHEMBL9151671 | 0.83 | KMT2A (0.55) | PRCPHTR2CHTR2BTLR2TERT | |
| SCHEMBL28750286 | 0.83 | KMT2A (0.55) | PRCPHTR2CHTR2BTLR2TERT | |
| SCHEMBL5097625 | 0.80 | PRCP (0.64) | PRCPHTR2CHTR2BTLR2TERT | |
| SCHEMBL5735106 | 0.80 | PRCP (0.64) | PRCPHTR2CHTR2BTLR2TERT | |
| SCHEMBL4578345 | 0.80 | PRCP (0.64) | PRCPHTR2CHTR2BTLR2TERT | |
| SCHEMBL21582234 | 0.80 | PRCP (0.64) | PRCPHTR2CHTR2BTLR2TERT | |
| SCHEMBL4578350 | 0.80 | PRCP (0.64) | PRCPHTR2CHTR2BTLR2TERT | |
| SCHEMBL2143309 | 0.79 | KMT2A (0.53) | PRCPHTR2CHTR2BTLR2TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281845-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | disclosed |
| US-7989441-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-20090069294-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-03-12 | — | — | US | disclosed |
| EP-1902065-A2 | CYCLIC AMIDE DERIVATIVES INHIBITORS OF THE INHIBITOR OF APOPTOSIS PROTEINS, THEIR PREPARATION, AND THEIR USE | Novartis AG (CH) | 2008-03-26 | — | — | EP | disclosed |
| WO-2006133147-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069294-A1 | Organic Compounds | XIAP, BAX, MCL1 | PRCP 2744/4885HTR2C 3877/4885HTR2B 3562/4885 |
| US-20110281845-A1 | ORGANIC COMPOUNDS | XIAP, BAX, MCL1 | PRCP 2745/4885HTR2C 3876/4885HTR2B 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.